Lily Bazak
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lily Bazak has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Gabriel Lidzbarsky
Raphael Recanati Genetic Institute, Rabin Medical Center‐Beilinson Hospital Petach Tikva Israel
2 shared publications - Lina Basel-Vanagaite
Innovation Division, Maccabi Healthcare Services, Tel Aviv, Israel
2 shared publications - Noa Ruhrman-Shahar
The Raphael Recanati Genetics Institute, Rabin Medical Center—Beilinson Hospital, Petah Tikva 49100, Israel
2 shared publications - Adel Shalata
The Simon Winter Institute for Human Genetics, Bnai Zion Medical Center, 47 Eliyahu Golomb Boulevard, Haifa 3339419, Israel
1 shared publication Alvit Veber
Metabolic Disease Unit, Edmond & Lily Safra Children’s Hospital, Tel-Hashomer, Israel (A.V., N.S.).
1 shared publication- Amitai Segev
The Leviev Heart Center, Sheba Medical Center , Sheba Rd. 2, Tel Hashomer, Ramat-Gan
1 shared publication
Latest Publications
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (1) , e004864
Mono and Biallelic Variants in TRIM63 Are Frequently Associated With a Unique Form of Hypertrophic Cardiomyopathy
- 1 February 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (1) , e004864
Mono and Biallelic Variants in TRIM63 Are Frequently Associated With a Unique Form of Hypertrophic Cardiomyopathy
- 24 September 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (1) , 369-372
A nonsense variant in the second exon of the canonical transcript of NSD1 does not cause Sotos syndrome
- 24 September 2021
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 188 (1) , 369-372
A nonsense variant in the second exon of the canonical transcript of NSD1 does not cause Sotos syndrome
- Open Access
- 18 February 2021
- Published by Wiley in Human Mutation
- Vol. 42 (5) , 592-599
Re‐evaluating the pathogenicity of the c.783+2T>C BAP1 germline variant
BAP1 germline pathogenic sequence variants (PSVs) underlie a unique tumor predisposition syndrome (BAP1 ‐ TPDS) associated with increased lifetime risk for developing primarily pleural and peritoneal mesothelioma and uveal and cutaneous melanoma. Overwhelmingly, BAP1 PSVs are unique, family specific inactivating variants. We identified seven families, 6 of Jewish Iraqi origin, harboring an identical BAP1 splice variant (c.783+2T>C), currently assigned a “likely pathogenic” status. Given a non‐classical BAP1‐TPDS tumor type clustering, and low penetrance in these families, the pathogenicity of this variant was re‐evaluated by a combined approach including literature analysis, revised bioinformatics analysis, allelic loss, effect on transcript, and tumor protein expression patterns. None of three available tumors showed allelic loss, there was no discernable effect on alternative splicing based on reverse transcription PCR, and there was no decrease or loss of somatic protein expression in 2/3 analyzed tumors. This led to assigning a Benign Strong (BS) criteria, BS4, supporting BS3 criteria, and to weakening the Pathogenic Supporting (PP) criteria PP5. Combined, these data suggest that this sequence variant should be re‐classified as a variant of unknown significance by ACMG criteria.
- 18 February 2021
- Published by Wiley in Human Mutation
- Vol. 42 (5) , 592-599
Open AccessRe‐evaluating the pathogenicity of the c.783+2T>C BAP1 germline variant
BAP1 germline pathogenic sequence variants (PSVs) underlie a unique tumor predisposition syndrome (BAP1 ‐ TPDS) associated with increased lifetime risk for developing primarily pleural and peritoneal mesothelioma and uveal and cutaneous melanoma. Overwhelmingly, BAP1 PSVs are unique, family specific inactivating variants. We identified seven families, 6 of Jewish Iraqi origin, harboring an identical BAP1 splice variant (c.783+2T>C), currently assigned a “likely pathogenic” status. Given a non‐classical BAP1‐TPDS tumor type clustering, and low penetrance in these families, the pathogenicity of this variant was re‐evaluated by a combined approach including literature analysis, revised bioinformatics analysis, allelic loss, effect on transcript, and tumor protein expression patterns. None of three available tumors showed allelic loss, there was no discernable effect on alternative splicing based on reverse transcription PCR, and there was no decrease or loss of somatic protein expression in 2/3 analyzed tumors. This led to assigning a Benign Strong (BS) criteria, BS4, supporting BS3 criteria, and to weakening the Pathogenic Supporting (PP) criteria PP5. Combined, these data suggest that this sequence variant should be re‐classified as a variant of unknown significance by ACMG criteria.